EUVIMEDEUVIMED entdecken
Crossref

Diagnostic Performance of 18 F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma

Camille Clement, Jean-Christophe Leclère, Clémentine Maheo, Romain Le Pennec, Gregoire Le Gal, Olivier Delcroix, Philippe Robin, Jean Rousset, Valentin Tissot, Aziliz Gueguen, Maryne Allio, Vincent Bourbonne und 4 weitere

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.124.267391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Camille Clement und 15 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Surgery Department, CHU of Brest, Brest, France. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Head and neck squamous cell carcinoma (HNSCC) remains a malignancy with high rates of locoregional recurrence and poor prognosis for recurrent cases. Early detection of subclinical lesions is challenging but critical for effective patient management. Imaging surveillance after treatment, particularly 18F-FDG PET/CT, has shown promise in the diagnosis of HNSCC recurrence. The aim was to evaluate the diagnostic performance of 18F-FDG PET/CT according to delay after treatment in detecting subclinical recurrence (SCR) in HNSCC patients.

Methods

In this retrospective study, all 18F-FDG PET/CT scans were performed at a single center. All adults with histologically proven HNSCC who were treated with curative intent between January 1, 2006, and December 31, 2021, were included. They had a normal clinical examination before each scan. Patients who underwent an intensive follow-up strategy after treatment had 18F-FDG PET/CT with an intravenous contrast agent at 3-6 mo and annually thereafter for 5 y. The primary endpoint was diagnostic performance (positive and negative predictive values, sensitivity, specificity, and accuracy).

Results

In total, 2,566 18F-FDG PET/CT scans were performed among 852 patients, with an average of 3 scans per patient. The overall diagnostic performance measures were as follows: positive predictive value (88%), negative predictive value (98%), sensitivity (98%), specificity (89%), and accuracy (93%). There were no significant differences in diagnostic performance over time. The scans detected 126 cases of SCR (14.8%) and 118 cases of metachronous cancer (13.8%). The incidence of SCR decreased over time, with the highest detection rate in the first 2 y after treatment. Positive predictive value improved over time, reaching 90% for the digital Vision 600 system (third period) compared with 76% for the analog Gemini GXLi system (first period, P < 0.001). Multivariate analysis identified advanced stage, high body mass index, and initial PET/CT upstaging as predictive factors for detection of SCR.

Conclusion

Our study demonstrates that 18F-FDG PET/CT has high diagnostic performance in detecting SCR during follow-up after treatment of HNSCC, especially in the first 2 y. Advanced tumor stage, initial PET/CT upstaging, and high body mass index were associated with a higher likelihood of SCR detection. The routine use of 18F-FDG PET/CT during follow-up seems justified for patients with HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographySquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and over

Stichwörter der Autor:innen

HNSCCPET/CTperformance

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Head and Neck Surgery Department, CHU of Brest, Brest, France.
  • Head and Neck Surgery Department, CHU of Brest, Brest, France; leclere.jean-christophe@hotmail.fr.
  • LIEN, University of Brest, Brest, France.
  • Nuclear Medicine Department, CHU of Brest, Brest, France.
  • UMR INSERM, 1304 GETBO, University of Brest, Brest, France.
  • Clinical Investigation Center, CIC 1412, CHU of Brest, Brest, France.

Zitieren

APA

Clement, C., Leclère, J. C., Maheo, C., Le Pennec, R., Le Gal, G., Delcroix, O., Robin, P., Rousset, J., Tissot, V., Gueguen, A., Allio, M., Bourbonne, V., Schick, U., Marianowski, R., Salaun, P. Y., & Abgral, R. (2024). Diagnostic Performance of 18 F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.267391

Vancouver

Clement C, Leclère JC, Maheo C, Le Pennec R, Le Gal G, Delcroix O, et al. Diagnostic Performance of 18 F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.124.267391

BibTeX
@article{Clement2024,
  author = {Clement, Camille and Leclère, Jean-Christophe and Maheo, Clémentine and Le Pennec, Romain and Le Gal, Gregoire and Delcroix, Olivier and Robin, Philippe and Rousset, Jean and Tissot, Valentin and Gueguen, Aziliz and Allio, Maryne and Bourbonne, Vincent and Schick, Ulrike and Marianowski, Remi and Salaun, Pierre-Yves and Abgral, Ronan},
  title = {Diagnostic Performance of 18 F-FDG PET/CT According to Delay After Treatment to Detect Subclinical Recurrence of Head and Neck Squamous Cell Carcinoma},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.124.267391}
}
Kostenlos starten →